The market for Type A hemophilia has shifted significantly, with JW Pharmaceutical's 'Hemlibra' expanding sales considerably after receiving reimbursement expansion.

However, Takeda Pharmaceutical’s 'Advate,' which has been recording the highest sales in the market for an extended period, lost ground. Advate sales decreased by over 20%, recording sales lower than Hemlibra’s.

Hemlibra sales KRW 7.6 billion → KRW 19 billion…As a result of acquiring reimbursement expansion

According to a pharmaceutical market research company IQVIA on the 8th, the market size of Type A hemophilia last year was KRW 77.1 billion, up 17% from KRW 66.2 billion in 2022. In this f